Clinical Trial: ECOG-ACRIN EA6134

ECOG-ACRIN EA6134

Status: Closed

NCT#02224781

DREAMseq (Doublet, Randomized Evaluation in Advanced Melanoma Sequencing) a Phase III Trial

EA6134 is closed to accrual, effective September 30, 2021.

The Montana Cancer Consortium (MCC) is an independent nonprofit organization whose mission is to bring state-of-the-art cancer care to Montana, Idaho and Wyoming through National Cancer Institute (NCI) sponsored clinical research.

Navigation

About Us

Contact Us

Copyright © Montana Cancer Consortium | All rights reserved